Novo Nordisk Pharma Logo

Novo Nordisk to license obesity drug from Lexicon

Novo Nordisk sets sights on new type of oral obesity drug

Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their weight loss when they stop taking Wegovy.

NBC New York · 1d

Novo Nordisk defends disappointing next-gen obesity drug: ‘It will be an important product'

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Reuters · 1d

Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish drugmaker's second deal this week, as it looks to strengthen the pipeline of its weight-loss treatments.

Fierce Biotech9d

'Not a cost-cutting exercise': Novo Nordisk CSO explains rationale behind pharma's R&D shake-up

Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has insisted that the changes aren’t primarily about laying off staff. | Novo ...

17h

The Woodlands-based company strikes obesity-drug license deal worth up to $1B

Lexicon Pharmaceuticals Inc. said March 28 it will exclusively license its drug candidate LX9851 to Danish pharmaceutical ...

Lexicon Pharmaceuticals, Novo Nordisk strike obesity-drug license deal worth up to $1B

Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX) said March 28 it will exclusively license its drug candidate LX9581 to Danish ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Novo Nordisk to license obesity drug from Lexicon

Trending now